Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy.

University of Tokyo, Tokyo, Japan.

Survival: monthsCountry:Japan
Toxiciy Grade:4City/State/Province:Tokyo
Treatments:ChemotherapyHospital:University of Tokyo
Drugs:Journal:Link
Date:Jun 2015

Description:

Patients:
This study involved 22 peripheral T cell lymphoma patients who had received prior treatment. The median patient age was 59 years and 64% were male.

Treatment:
Patients received the chemotherapy regimen called mESHAP, which consisted of etoposide, methylprednisolone, high-dose cytarabine, and carboplatin.

Toxicities:
The most severe toxicities were of grade 4 and included leukopenia, anemia, and thrombocytopenia.

Results:
The median overall survival was 11.0 months.

Support:
Some of the study authors have received past funding from various pharmaceutical companies.

Correspondence: Dr. Mineo Kurokawa; email: [email protected]



Back